Ignite Creation Date:
2024-05-06 @ 7:55 PM
Last Modification Date:
2024-10-26 @ 3:17 PM
Study NCT ID:
NCT06187402
Status:
RECRUITING
Last Update Posted:
2024-01-05
First Post:
2023-12-04
Brief Title:
A Study of LM-24C5 For Advanced Solid Tumors
Sponsor:
LaNova Medicines Limited
Organization:
LaNova Medicines Limited
Study Overview
Official Title:
A Phase III First-in-Human FIH Open-Label Multiple Centre Clinical Study to Evaluate the Safety Tolerability Pharmacokinetics Immunogenicity and Preliminary Efficacy of LM-24C5 in Patients With Advanced Solid Tumors
Status:
RECRUITING
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To assess the safety and tolerability obtain the recommended phase 2 dose RP2Doptimal biologic dose OBD andor Maximum Tolerated Dose MTD for LM-24C5 in subjects with advanced solid tumors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None